NCT03039790

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 528 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 NoV vaccine administration.

Detailed description

Results prepared and posted by Takeda on behalf of Hillevax, the IND holder. The drug being tested in this study is called NoV vaccine. NoV vaccine is being tested for protection against acute gastroenteritis (AGE) due to norovirus. The study will enroll maximum of approximately 575 participants. Participants who previously received NoV vaccine in studies NOR-107, NOR-210 and NOR-204 will be enrolled. Participants from study NOR-107 will enter the study at the time of their 3rd year post-primary vaccination, and from studies NOR-210 and NOR-204, at their 2nd year post-primary vaccination. The duration of participation in the study will be different for each participant. This multi-center trial will be conducted in Belgium and the United States. The overall time to participate in this study is maximum 5 years after primary NoV vaccination. Participants will have a maximum of 4 visits over 3 years

Conditions

• Healthy Volunteers
• Norovirus

Interventions

Type	Name	Description
BIOLOGICAL	NoV Vaccine	NoV vaccine injection administered.

Timeline

• Start date: 2017-02-21
• Primary completion: 2021-07-22
• Completion: 2021-07-22
• First posted: 2017-02-01
• Last updated: 2022-11-09
• Results posted: 2022-10-06

Locations

11 sites across 2 countries: United States, Belgium

Regulatory

• FDA-regulated drug study